98%
921
2 minutes
20
This study was conducted to develop a lipid/clay-based solid dispersion (LSD) formulation to enhance the dissolution and oral bioavailability of poorly soluble curcumin. Krill oil and aminoclay were used as a lipid and a stabilizer, respectively, and LSD formulations of curcumin were prepared by an antisolvent precipitation method combined with freeze-drying process. Based on the dissolution profiles, the optimal composition of LSD was determined at the weight ratio of curcumin: krill oil: aminoclay of 1:5:5 in the presence of 0.5% of D-α-tocopherol polyethylene glycol succinate. The structural and morphological characteristics of the LSD formulation were determined using X-ray powder diffraction, differential scanning calorimetry, and scanning electron microscopy. Crystalline curcumin was changed to an amorphous form in the LSD formulation. At the pH of acidic to neutral, the LSD formulation showed almost complete drug dissolution (>90%) within 1 h, while pure curcumin exhibited minimal dissolution of less than 10%. Furthermore, the LSD formulation had significantly improved oral absorption of curcumin in rats, where Cmax and AUC of curcumin were 13- and 23-fold higher for the LSD formulation than for the pure drug. Taken together, these findings suggest that the krill oil-based solid dispersion formulation of curcumin effectively improves the dissolution and oral bioavailability of curcumin.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697399 | PMC |
http://dx.doi.org/10.3390/pharmaceutics14112269 | DOI Listing |
Importance: Effective and well-tolerated pharmacotherapies for generalized anxiety disorder (GAD), which is one of the most common psychiatric disorders, are needed.
Objective: To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD.
Design, Settings, And Participants: This phase 2b, multicenter, randomized, double-blind, placebo-controlled study enrolled 198 adults aged 18 to 74 years with a primary GAD diagnosis who presented with moderate to severe symptoms (defined by a Hamilton Anxiety Rating Scale [HAM-A] score ≥20) and was conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023.
Trop Anim Health Prod
August 2025
School of Agricultural Sciences and Technology, Animal Production and Technology Department, Chinhoyi University of Technology, Chinhoyi, Zimbabwe.
Antimicrobial drug resistance from improper use of antibiotics in broiler chicken production is a growing hazard for humans worldwide. A feasibility study was conducted to evaluate growth, immunity and carcass traits of commercial broiler chickens fed water-distributed biosurfactants, from gastrointestinal tract derived Escherichia coli related microbe, as regular feed additives. Ninety-nine Cobb500 broiler chickens, housed in a curtained open-sided pen utilizing a deep litter system, were randomly allocated to three dietary treatments (biosurfactant based, negative -no drug added and positive control -with antibiotic drug plus NCD vaccination done), replicated thrice (11 broiler chickens per replicate).
View Article and Find Full Text PDFVet Med Sci
September 2025
Department of Pathology, Faculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, Bangladesh.
Objectives: Lumpy skin disease (LSD) is a transboundary viral pox disease that causes huge economic losses. The disease is in an epidemic situation, and the affected cattle show massive lesions and complexity, which is tough to treat; thus, a study was conducted to investigate the clinico-haematological alterations of LSD-affected cattle for adopting better pharmacotherapeutic management.
Material And Methods: A total of 36 LSD affected, and 8 healthy/control cattle were examined and used for blood profiling.
Pharmaceutics
June 2025
Matériaux et Santé, Université Paris-Saclay, 91400 Orsay, France.
D-lysergic acid diethylamide (D-LSD) is under investigation as a potential therapeutic strategy for alcohol use disorder (AUD). However, the extreme light sensitivity of D-LSD presents a significant challenge in developing suitable pharmaceutical forms, particularly for clinical trial settings. This study proposes a liquid-filled capsule formulation designed to provide accurate dosing while protecting D-LSD from photodegradation.
View Article and Find Full Text PDF